From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

BREAKING: The whole Steve O Hara health story Optibiotix is still not telling you

By Tom Winnifrith, the Sheriff of AIM | Friday 1 November 2024


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


The GM called by Seneca in cahoots with Optibiotix (OPTI) to sack Steen Anderson at Probiotix (PBX) is over and as we knew would happen, the motion was rejected. I gather that at least one PDMR at Probiotix has already bought shares in the company as a result and more insider buying, of a material nature, will follow next week. Things are all good at Probiotix and at 4p-6p folks should just hold their nose when it comes to the spread and buy. My two year target remains 24p. But I have shocking news about Optibiotix.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

Time left: 22:19:33